1. Akbarian S, Vinuela A, Kim JJ, Potkin SG, Bunney WE Jr., Jones EG. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187.

 2. Akbarian S, Vinuela A, Kim JJ, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances in cortical development. Arch Gen Psychiatry 1993;50:169-177.

 3. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30.

 4. Arnold SE, Hyman BT, van Hoesen GW, Damasio AR. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991;48:625-632.

 5. Borden LA, Bell SC, Ognyanov VI, et al. Glycine transport inhibitors as novel antipsychotic agents. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 200.

 6. Bosomworth PP. Ketamine symposium—comments by moderator. Anesth Analg 1971;50:471-479.

 7. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-343.

 8. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 1995;674:82-90.

 9. Buchsbaum MS, Haier RJ, Potkin SG, et al. Frontostriatal disorders of cerebral metabolism in never-medicated schizophrenics. Arch Gen Psychiatry 1992;49:945-942.

10. Buchsbaum MS. Positron emission tomography studies of abnormal glucose metabolism in schizophrenic illness. Clin Neurosci 1995;3:122-130.

11. Bunney BG, Bunney WE, Jr, Carlsson A. Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The fourth generation of progress. New York, Raven Press, 1995;1205-1214.

12. Carlsson A. The current status of the DA hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-186.

13. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study. J Neural Transm 1994;95:105-111.

14. Collinge J, Curtis D. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Brit J Psychiatry 1991;159:857-859.

15. Corssen G, Domino EF. Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine deritive Cl-581. Anesth Analg 1966;45:29-40.

16. Costa J, Khaled E, Sramek J, Bunney W, Jr., Potkin SG. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. J Clin Psychopharmacol 1990;10:71-72.

17. Crosby G, Crane AM, Sokoloff L. Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiology 1982;56:437-443.

18. DeSouza DC, Abi-Saab D, Damon D, White J, Gil R, Krystal JH. Dose response of D-cycloserine, a partial NMDA-glycine site agonist, in schizophrenia. Abstract. XXth CINP Congress, Melbourne, June 23-27, 1996, No.O-22-11.

19. Davies BM, Beech HR. The effect of 1-arylcyclohexamine (Sernyl) on twelve normal volunteers. J Mental Sci 1960;106:912-924.

20. Davis DW, Mans AM, Biebuyck JF, Phil D, Hawkins RA. The influence of ketamine on regional brain glucose use. Anesthesiology 1988;69:199-205.

21. Deakin JF, Slater P, Simpson MD, et al. Frontal cortical and left temporal glutamategic dysfunction in schizophrenia. J Neurochem 1989;52:1781-1786.

22. Deutsch SI, Mastraopoalo Y, Schwartz BL, Rosse RB, Morihisa JM. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12:1-13.

23. Do KQ, Lauer CJ, Schreiber W, et al. gamma-glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995; 65:2652-2662.

24. Domino EF, Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino EF, ed. PCP (Phencyclidine): Historical and current perspectives. Michigan: NPP Books, 1981;401-418.

25. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995;29:211-223.

26. Gao XM, Shirikawa O, Tamminga CA. Delayed phencyclidine-induced alterations in local cerebral glucose utilization in rat brain. Neurosci Abs 1991;575:1473.

27. Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982;231:221-225.

28. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 1995;152:1213-1215.

29. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 1996;153:12:1628-1630.

30. Goff DC, Tsai T, Levit J, Amico E, McCarley R. Placebo-controlled trial of d-cycloserine added to conventional neuroleptics. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 200.

31. Hammer RP, Jr, Herkenham M. Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 1983;220:396-404.

32. Hartvig P, Valtysson J, Lindner KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther 1995;58:165-173.

33. Heresco-Levy U, Javitt DC, Zukin SR. The phencyclidine/N-methyl-D-aspartate (PCP/NMDA) model of schizophrenia: Theoretical and clinical implications. Psychiatr Ann 1993;23:135-143.

34. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Brit J Psychiatry 1996;169:610-617.

35. Ishimaru M, Kurumaji A, Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 1992;32:379-381.

36. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65:303-326.

37. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.

38. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer J-P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-1236.

39. Javitt D.C. Glycine and glycine uptake antagonists in the treatment of schizophrenia. Abstract, 35th Annual Meeting of the ACNP, December 9-13,1996, San Juan, Puerto Rico. p. 201.

40. Johnstone M, Evans V, Baigel S. Sernyl (Cl-395) in clinical anaesthesia. J Anaesth 1959;31:433-439.

41. Judd LL, McAdams L, Budnick B, Braff DL. Sensory gating deficits in schizophrenia: new results. Am J Psychiatry 1992;149:488-493.

42. Kerwin RW, Patel S, Meldrum BS, Czudek C, Reynolds GP. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet 1988;1:583-584.

43. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate receptor binding sites in the hippocampal formation in normal and schizophrenic postmortem brain. Neuroscience 1990;39:25-32.

44. Kerwin R. Glutamatergic abnormalities in the temporal lobe in schizophrenia. Abstract. XXth CINP Congress, Melbourne, June 23-27, 1996, No.S-30-2.

45. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis of schizophrenia. Neurosci Lett 1980;20:379-382.

46. Kornhuber J, Mack-Burkhardt F, Hebenstreit GF, Reynolds GP, Andrews HB, Beckmann H. 3H-MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989;77:231-236.

47. Kornhuber J, Mack-Burkhardt F, Riederer P. Regional distribution of 3H-MK-801 binding sites in the human brain. Brain Res 1989;489:397-399.

48. Korpi ER, Kaufmann CA, Marnela KM, Weinberger DR. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatr Res 1987;20:337-345.

49. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994;51:199-214.

50. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995;13: 9-19.

51. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA. Ketamine activates psychosis and alters blood flow in schizophrenia. NeuroReport 1995;6:869-872.

52. Lasagna L, Pearson JW. Analgesic and psychotomimetic properties of dexoxadrol. Proc Soc Exp Biology Med 1965;118: 352-354.

53. Li Y, Erzurumlu, Chen C, Jhaveri S, Tonegawa S. Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice. Cell 1994;76:427-437.

54. Luby ED, Cohen BD, Rosenbaum F, Gottlieb J, Kelley R. Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 1959;81:363-369.

55. Luby ED. Phencyclidine revisited. In: Domino EF ed. PCP (Phencyclidine): Historical and current perspectives. Michigan: NPP Books,1981:425-430.

56. MacDonald JF, Mody I, Salter MW, Pennefather P, Schneiderman JH. The regulation of NMDA receptors in the central nervous system. Prog Neuro-psychopharmacol Biol Psychiatry 1989;13:481-488.

57. Malhotra AK, Pinals DA, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996;14:301-307.

58. Mansbach RS, Geyer MA. Parametric determinants in pre-stimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology 1991;105:162-168.

59. Maragos WF, Chu DCM, Greenamyre T, Penney JB, Young AB. High correlation between the localization of 3H-TCP and NMDA receptors. Eur J Pharmacol 1986;123:173-174.

60. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.

61. Nehls DG, Kurumaji A, Park CK, McCulloch J. Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neurosci Lett 1988;91:204-210.

62. Nelson SR, Howard RB, Cross RS, Samson F. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology 1980;52:330-334.

63. Nishikawa T, Takashima M, Toru M. Increased 3H-kainate acid binding in the prefrontal cortex of schizophrenics. Neurosci Lett 1983;40:245-250.

64. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett 1982;28: 81-85.

65. Piercey MF, Ray CA. Dramatic limbic and cortical effects mediated by high affinity PCP receptors. Life Sci 1988;43:379-385.

66. Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulaskaram B: Glycine in the treatment of schizophrenia: theory and preliminary results. In Novel antipsychotic drugs. Meltzer HY (ed). New York, Raven Press, 179-188,1992.

67. Rosenbaum G, Cohen B, Luby ED, Gottlieb JS, Yelen D. Comparison of Sernyl with other drugs. Arch Gen Psychiatry 1959;1:651-656.

68. Rosse RB, Theut S, Banay-Schwartz M, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label pilot study. Clin Neuropharmacol 1989;12:416-424.

69. Rosse RB, Schwartz BL, Davis RE, Deutsch SI. An NMDA intervention strategy in schizophrenia with "low dose" milacemide. Clin Neuropharmacol 1991;14:268-272.

70. Sadove MS, Shulman M, Hatano S, Fevold N. Analgesic effects of ketamine administered in subdissociative doses. Anesth Analg 1971;50:452-457.

71. Saija A., Princi P, DePasquale R, Costa G. Modifications of the permeability of the blood-brain barrier and local cerebral metabolism in pentobarbital- and ketamine-anaesthetized rats. Neuropharmacology 1989;28:997-1002.

72. Simopoulos AM, Pinto A, Babikow PW, Kurland A, Savage C. Psychotomimetic properties and therapeutic potentials of dexoxadrol on convalescing alcoholics. Dis Nervous Syst 1970;31:203-207.

73. Simpson MDC, Slater P, Royston MC, Deakin JFW. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: Effects of disease process and neuroleptic medication. Schizophrenia Res 1992;6:41-48.

74. Strous RD, Javitt JC. The N-methyl-D-aspartate receptor and schizophrenia. Isr J Med 1996;32:275-281.

75. Tamminga CA, Tanimoto K, Kuo S, et al. PCP-induced alterations in cerebral glucose metabolism in rat brain: Blockade by Metaphit, a PCP receptor acylating agent. Synapse 1987;1:497-504,.

76. Tamminga CA, Thanker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992;49:522-530.

77. Toru M, Watanabe S, Shibuya H, et al. Neurotransmitters, receptors, and neuropeptides in postmortem brains of schizophrenics. Acta Psychiatr Scand 1988;78:121-137.

78. Tsai G, Passani LA, Slusher BS, Carter R, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-836.

79. van Berckel BNM, Hijman R, van der Linden JA, Westenberg HGM, van Ree JM, Kahn RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 1996;40:1298-1300.

80. Waziri R: Glycine therapy of schizophrenia. Biol Psychiatry 1988; 23:210.

81. Waziri R, Baruah S, Sherman AD. Abnormal serine-glycine metabolism in the brains of schizophrenics. Neurosci Lett 1992;120:237-240.

82. Weissman AD, Dam M, London ED. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 1987;435:29-40.

83. Weissman AD, Casanova MF, Kleinman E, London ED, DeSouza EB. Selective loss of cerebral sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 1991;29:41-54.

84. Weissman AD, Casanova MF, Kleinman JE, and DeSouza EB. PCP and sigma receptors in brain are not altered after repeated exposure to PCP in humans. Neuropsychopharmacology 1991;4:95-102.

85. Williams MW, Williford WA, Williams CS, Towne JC. Clinical analgesic activity of dexoxadrol. Arch Int Pharmacodyn 1969;178:26-30.